1
|
Hall S, Ward ND, Patel R, Amin-Javaheri A, Lanford H, Grespin RT, Couch C, Xiong Y, Mukherjee R, Jones JA, Ruddy JM. Mechanical activation of the angiotensin II type 1 receptor contributes to abdominal aortic aneurysm formation. JVS Vasc Sci 2021; 2:194-206. [PMID: 34761239 PMCID: PMC8567200 DOI: 10.1016/j.jvssci.2021.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 07/14/2021] [Indexed: 12/22/2022] Open
Abstract
Objective The angiotensin II type 1 receptor (AT1R) can be activated under conditions of mechanical stretch in some cellular systems. Whether this activity influences signaling within the abdominal aorta to promote to abdominal aortic aneurysm (AAA) development remains unknown. We evaluated the hypothesis that mechanical AT1R activation can occur under conditions of hypertension (HTN) and contribute to AAA formation. Methods BPH/2 mice, which demonstrate spontaneous neurogenic, low-renin HTN, and normotensive BPN/3 mice underwent AAA induction via the calcium chloride model, with or without an osmotic minipump delivering 30 mg/kg/d of the AT1R blocker Losartan. Systolic blood pressure (SBP) was measured at baseline and weekly via a tail cuff. The aortic diameter (AoD) was measured at baseline and terminal surgery at 21 days by digital microscopy. Aortic tissue was harvested for immunoblotting (phosphorylated extracellular signal-regulated kinase-1 and -2 [pERK1/2] to ERK1/2 ratio) and expressed as the fold-change from the BPN/3 control mice. Aortic vascular smooth muscle cells (VSMCs) underwent stretch with or without Losartan (1 μM) treatment to assess the mechanical stimulation of ERK1/2 activity. Statistical analysis of the blood pressure, AoD, and VSMC ERK1/2 activity was performed using analysis of variance. However, the data distribution was determined to be log-normal (Shapiro-Wilk test) for ERK1/2 activity. Therefore, it was logarithmically transformed before analysis of variance. Results At baseline, the SBP was elevated in the BPH/2 mice relative to the BPN/3 mice (P < .05). Losartan treatment significantly reduced the SBP in both mouse strains (P < .05). AAA induction did not affect the SBP. At 21 days after induction, the percentage of increase in the AoD from baseline was significantly greater in the BPH/2 mice than in the BPN/3 mice (101.28% ± 4.19% vs 75.59% ± 1.67% above baseline; P < .05). Losartan treatment significantly attenuated AAA growth in both BPH/2 and BPN/3 mice (33.88% ± 2.97% and 43.96% ± 3.05% above baseline, respectively; P < .05). ERK1/2 activity was increased approximately fivefold in the BPH/2 control mice relative to the BPN/3 control mice (P < .05). In the BPH/2 and BPN/3 mice with AAA, ERK1/2 activity was significantly increased relative to the respective baseline control (P < .05) and effectively reduced by concomitant Losartan therapy (P < .05). Biaxial stretch of the VSMCs in the absence of angiotensin II demonstrated increased ERK1/2 activation (P < .05 vs static control), which was significantly inhibited by Losartan. Conclusions In BPH/2 mice with spontaneous neurogenic, low-renin HTN, AAA growth was amplified compared with the normotensive control and was effectively attenuated using Losartan. ERK1/2 activity was significantly elevated in the BPH/2 mice and after AAA induction in the normotensive and hypertensive mice but was attenuated by Losartan treatment. These data suggest that AT1R activation contributes to AAA development. Therefore, further investigation into this signaling pathway could establish targets for pharmacotherapeutic engineering to slow AAA growth. (JVS-Vascular Science 2021;2:194-206.). Clinical Relevance Hypertension (HTN) and abdominal aortic aneurysm (AAA) have been epidemiologically linked for decades; however, a biomechanical link has not yet been identified. Using a murine model of spontaneous neurogenic HTN experimentally demonstrated to have low circulating renin, mechanical activation of the angiotensin II type 1 receptor (AT1R) was identified with elevated blood pressure and AAA induction. HTN amplified AAA growth. However, more importantly, blocking the activation of AT1R with the angiotensin receptor blocker Losartan effectively abrogated AAA development. Although inhibiting the production of angiotensin II has previously been unsuccessful in altering AAA growth, the results from the present study suggest that blocking the activation of AT1R through direct ligand binding or mechanical stimulation might alter aortic wall signaling and warrants further investigation.
Collapse
Affiliation(s)
- SarahRose Hall
- Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC
| | - Nicholas D Ward
- Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC
| | - Raj Patel
- Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC
| | - Armaan Amin-Javaheri
- Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC
| | - Hayes Lanford
- Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC
| | - R Tyler Grespin
- Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC
| | - Christine Couch
- Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC
| | - Ying Xiong
- Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC
| | - Rupak Mukherjee
- Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC.,Ralph H. Johnson VA Medical Center, Charleston, SC
| | - Jeffrey A Jones
- Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC.,Ralph H. Johnson VA Medical Center, Charleston, SC
| | - Jean Marie Ruddy
- Division of Vascular Surgery, Medical University of South Carolina, Charleston, SC.,Ralph H. Johnson VA Medical Center, Charleston, SC
| |
Collapse
|
2
|
Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog. Nat Struct Mol Biol 2018; 25:570-576. [PMID: 29967536 DOI: 10.1038/s41594-018-0079-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Accepted: 04/26/2018] [Indexed: 12/12/2022]
Abstract
Angiotensin II (AngII) plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngII and the G-protein-coupled receptors (GPCRs) AngII type 1 receptor (AT1R) and AngII type 2 receptor (AT2R). We have solved the crystal structure of human AT2R binding the peptide ligand [Sar1, Ile8]AngII and its specific antibody at 3.2-Å resolution. [Sar1, Ile8]AngII interacts with both the 'core' binding domain, where the small-molecule ligands of AT1R and AT2R bind, and the 'extended' binding domain, which is equivalent to the allosteric modulator binding site of muscarinic acetylcholine receptor. We generated an antibody fragment to stabilize the extended binding domain that functions as a positive allosteric modulator. We also identified a signature positively charged cluster, which is conserved among peptide-binding receptors, to locate C termini at the bottom of the binding pocket. The reported results should help with designing ligands for angiotensin receptors and possibly to other peptide GPCRs.
Collapse
|
3
|
Zhang Z, Tang W. Drug metabolism in drug discovery and development. Acta Pharm Sin B 2018; 8:721-732. [PMID: 30245961 PMCID: PMC6146880 DOI: 10.1016/j.apsb.2018.04.003] [Citation(s) in RCA: 161] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 03/25/2018] [Accepted: 04/02/2018] [Indexed: 11/27/2022] Open
Abstract
Drug metabolism as a discipline plays an important role in drug discovery and development and the effects of drug metabolism on pharmacokinetics (PK), pharmacodynamics (PD), and safety should be carefully considered. This communication provides an overview of common strategies in the area of drug metabolism for improving PK/PD and safety profiles of drug candidates; these include, but are not limited to, collaboration with medicinal chemists on structure–activity relationships (SAR) to overcome high clearance, using deuterium replacement to further optimize a lead, prodrug approaches to circumvent formulation and delivery difficulties, and addressing issues such as species differences in metabolism, drug–drug interactions (DDI) and formation of reactive metabolites.
Collapse
|
4
|
Takezako T, Unal H, Karnik SS, Node K. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism. Pharmacol Res 2017. [PMID: 28648738 DOI: 10.1016/j.phrs.2017.06.013] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Although the octapeptide hormone angiotensin II (Ang II) regulates cardiovascular and renal homeostasis through the Ang II type 1 receptor (AT1R), overstimulation of AT1R causes various human diseases, such as hypertension and cardiac hypertrophy. Therefore, AT1R blockers (ARBs) have been widely used as therapeutic drugs for these diseases. Recent basic research and clinical studies have resulted in the discovery of interesting phenomena associated with AT1R function. For example, ligand-independent activation of AT1R by mechanical stress and agonistic autoantibodies, as well as via receptor mutations, has been shown to decrease the inverse agonistic efficacy of ARBs, though the molecular mechanisms of such phenomena had remained elusive until recently. Furthermore, although AT1R is believed to exist as a monomer, recent studies have demonstrated that AT1R can homodimerize and heterodimerize with other G-protein coupled receptors (GPCR), altering the receptor signaling properties. Therefore, formation of both AT1R homodimers and AT1R-GPCR heterodimer may be involved in the pathogenesis of human disease states, such as atherosclerosis and preeclampsia. Finally, biased AT1R ligands that can preferentially activate the β-arrestin-mediated signaling pathway have been discovered. Such β-arrestin-biased AT1R ligands may be better therapeutic drugs for cardiovascular diseases. New findings on AT1R described herein could provide a conceptual framework for application of ARBs in the treatment of diseases, as well as for novel drug development. Since AT1R is an extensively studied member of the GPCR superfamily encoded in the human genome, this review is relevant for understanding the functions of other members of this superfamily.
Collapse
Affiliation(s)
- Takanobu Takezako
- Department of Advanced Heart Research, Saga University, Saga, Japan; Medical Center for Student Health, Kobe University, Kobe, Japan.
| | - Hamiyet Unal
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Sadashiva S Karnik
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Koichi Node
- Department of Cardiovascular Medicine, Saga University, Japan
| |
Collapse
|
5
|
Takezako T, Unal H, Karnik SS, Node K. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor. Mol Pharmacol 2015; 88:488-501. [PMID: 26121982 DOI: 10.1124/mol.115.099176] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 06/29/2015] [Indexed: 01/05/2023] Open
Abstract
Ligand-independent signaling by the angiotensin II type 1 receptor (AT1R) can be activated in clinical settings by mechanical stretch and autoantibodies as well as receptor mutations. Transition of the AT1R to the activated state is known to lower inverse agonistic efficacy of clinically used AT1R blockers (ARBs). The structure-function basis for reduced efficacy of inverse agonists is a fundamental aspect that has been understudied not only in relation to the AT1R but also regarding other homologous receptors. Here, we demonstrate that the active-state transition in the AT1R indeed attenuates an inverse agonistic effect of four biphenyl-tetrazole ARBs through changes in specific ligand-receptor interactions. In the ground state, tight interactions of four ARBs with a set of residues (Ser109(TM3), Phe182(ECL2), Gln257(TM6), Tyr292(TM7), and Asn295(TM7)) results in potent inverse agonism. In the activated state, the ARB-AT1R interactions shift to a different set of residues (Val108(TM3), Ser109(TM3), Ala163(TM4), Phe182(ECL2), Lys199(TM5), Tyr292(TM7), and Asn295(TM7)), resulting in attenuated inverse agonism. Interestingly, V108I, A163T, N295A, and F182A mutations in the activated state of the AT1R shift the functional response to the ARB binding toward agonism, but in the ground state the same mutations cause inverse agonism. Our data show that the second extracellular loop is an important regulator of the functional states of the AT1R. Our findings suggest that the quest for discovering novel ARBs, and improving current ARBs, fundamentally depends on the knowledge of the unique sets of residues that mediate inverse agonistic potency in the two states of the AT1R.
Collapse
Affiliation(s)
- Takanobu Takezako
- Department of Advanced Heart Research, Saga University, Saga, Japan (T.T.); Department of Cardiovascular Medicine, Saga University, Saga, Japan (K.N.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio (H.U., S.S.K.); Department of Biosignal Pathophysiology, Kobe University Graduate School of Medicine, Kobe, Japan (T.T.); and Department of Basic Sciences, Faculty of Pharmacy and Betul Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey (H.U.)
| | - Hamiyet Unal
- Department of Advanced Heart Research, Saga University, Saga, Japan (T.T.); Department of Cardiovascular Medicine, Saga University, Saga, Japan (K.N.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio (H.U., S.S.K.); Department of Biosignal Pathophysiology, Kobe University Graduate School of Medicine, Kobe, Japan (T.T.); and Department of Basic Sciences, Faculty of Pharmacy and Betul Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey (H.U.)
| | - Sadashiva S Karnik
- Department of Advanced Heart Research, Saga University, Saga, Japan (T.T.); Department of Cardiovascular Medicine, Saga University, Saga, Japan (K.N.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio (H.U., S.S.K.); Department of Biosignal Pathophysiology, Kobe University Graduate School of Medicine, Kobe, Japan (T.T.); and Department of Basic Sciences, Faculty of Pharmacy and Betul Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey (H.U.)
| | - Koichi Node
- Department of Advanced Heart Research, Saga University, Saga, Japan (T.T.); Department of Cardiovascular Medicine, Saga University, Saga, Japan (K.N.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio (H.U., S.S.K.); Department of Biosignal Pathophysiology, Kobe University Graduate School of Medicine, Kobe, Japan (T.T.); and Department of Basic Sciences, Faculty of Pharmacy and Betul Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey (H.U.)
| |
Collapse
|
6
|
Unal H, Karnik SS. Constitutive activity in the angiotensin II type 1 receptor: discovery and applications. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2014; 70:155-74. [PMID: 24931196 DOI: 10.1016/b978-0-12-417197-8.00006-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The pathophysiological actions of the renin-angiotensin system hormone, angiotensin II (AngII), are mainly mediated by the AngII type 1 (AT1) receptor, a GPCR. The intrinsic spontaneous activity of the AT1 receptor in native tissues is difficult to detect due to its low expression levels. However, factors such as the membrane environment, interaction with autoantibodies, and mechanical stretch are known to increase G protein signaling in the absence of AngII. Naturally occurring and disease-causing activating mutations have not been identified in AT1 receptor. Constitutively active mutants (CAMs) of AT1 receptor have been engineered using molecular modeling and site-directed mutagenesis approaches among which substitution of Asn(111) in the transmembrane helix III with glycine or serine results in the highest basal activity of the receptor. Transgenic animal models expressing the CAM AT1 receptors that mimic various in vivo disease conditions have been useful research tools for discovering the pathophysiological role of AT1 receptor and evaluating the therapeutic potential of inverse agonists. This chapter summarizes the studies on the constitutive activity of AT1 receptor in recombinant as well as physiological systems. The impact of the availability of CAM AT1 receptors on our understanding of the molecular mechanisms underlying receptor activation and inverse agonism is described.
Collapse
Affiliation(s)
- Hamiyet Unal
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Sadashiva S Karnik
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
| |
Collapse
|
7
|
Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev 2013; 65:578-640. [PMID: 23406671 DOI: 10.1124/pr.111.005439] [Citation(s) in RCA: 104] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Metabolism represents the most prevalent mechanism for drug clearance. Many drugs are converted to metabolites that can retain the intrinsic affinity of the parent drug for the pharmacological target. Drug metabolism redox reactions such as heteroatom dealkylations, hydroxylations, heteroatom oxygenations, reductions, and dehydrogenations can yield active metabolites, and in rare cases even conjugation reactions can yield an active metabolite. To understand the contribution of an active metabolite to efficacy relative to the contribution of the parent drug, the target affinity, functional activity, plasma protein binding, membrane permeability, and pharmacokinetics of the active metabolite and parent drug must be known. Underlying pharmacokinetic principles and clearance concepts are used to describe the dispositional behavior of metabolites in vivo. A method to rapidly identify active metabolites in drug research is described. Finally, over 100 examples of drugs with active metabolites are discussed with regard to the importance of the metabolite(s) in efficacy and safety.
Collapse
Affiliation(s)
- R Scott Obach
- Pfizer Inc., Eastern Point Rd., Groton, CT 06340, USA.
| |
Collapse
|
8
|
Nistala R, Andresen BT, Pulakat L, Meuth A, Sinak C, Mandavia C, Thekkumkara T, Speth RC, Whaley-Connell A, Sowers JR. Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. Am J Physiol Renal Physiol 2013; 304:F1105-13. [PMID: 23389452 DOI: 10.1152/ajprenal.00127.2012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Blockade of the angiotensin (ANG) II receptor type 1 (AT(1)R) with angiotensin receptor blockers (ARBs) is widely used in the treatment of hypertension. However, ARBs are variably effective in reducing blood pressure, likely due, in part, to polymorphisms in the ARB binding pocket of the AT(1)R. Therefore, we need a better understanding of variations/polymorphisms that alter binding of ARBs in heterogeneous patient populations. The opossum proximal tubule cell (OKP) line is commonly used in research to evaluate renal sodium handling and therefore blood pressure. Investigating this issue, we found natural sequence variations in the opossum AT(1)R paralleling those observed in the human AT(1)R. Therefore, we posited that these sequence variations may explain ARB resistance. We demonstrate that OKP cells express AT(1)R mRNA, bind (125)I-labeled ANG II, and exhibit ANG II-induced phosphorylation of Jak2. However, Jak2 phosphorylation is not inhibited by five different ARBs commonly used to treat hypertension. Additionally, nonradioactive ANG II competes (125)I-ANG II efficiently, whereas a 10-fold molar excess of olmesartan and the ANG II receptor type 2 blocker PD-123319 is unable to block (125)I-ANG II binding. In contrast, ANG II binding to OKP cells stably expressing rat AT(1A)Rs, which have a conserved AT(1)R-binding pocket with human AT(1)R, is efficiently inhibited by olmesartan. A novel observation was that resistance to ARB binding to opossum AT(1)Rs correlates with variations from the human receptor at positions 108, 163, 192, and 198 within the ARB-binding pocket. These observations highlight the potential utility of evaluating AT(1)R polymorphisms within the ARB-binding pocket in various hypertensive populations.
Collapse
Affiliation(s)
- Ravi Nistala
- Division of Nephrology, Department of Internal Medicine, University of Missouri-Columbia, Columbia, MO 65212, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Naik P, Murumkar P, Giridhar R, Yadav MR. Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists—A perspective. Bioorg Med Chem 2010; 18:8418-56. [DOI: 10.1016/j.bmc.2010.10.043] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Revised: 10/14/2010] [Accepted: 10/15/2010] [Indexed: 10/18/2022]
|
10
|
Miura SI, Saku K. Do angiotensin II type 1 receptor blockers have molecular effects? Hypertens Res 2009; 33:105-6. [PMID: 19942930 DOI: 10.1038/hr.2009.202] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Shin-Ichiro Miura
- Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
| | | |
Collapse
|
11
|
Demaegdt H, Lukaszuk A, De Buyser E, De Backer JP, Szemenyei E, Tóth G, Chakravarthy S, Panicker M, Michotte Y, Tourwé D, Vauquelin G. Selective labeling of IRAP by the tritiated AT(4) receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11. Mol Cell Endocrinol 2009; 311:77-86. [PMID: 19643163 DOI: 10.1016/j.mce.2009.07.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2009] [Revised: 07/14/2009] [Accepted: 07/21/2009] [Indexed: 11/22/2022]
Abstract
'AT(4) receptors' through which Angiotensin IV (Ang IV) improves memory acquisition, were recently identified as insulin regulated aminopeptidase (IRAP). Radioligand binding studies have hitherto been performed with iodinated Ang IV in the presence of divalent cation chelators EDTA and 1,10-phenanthrolin. Hence, they referred to the apo-form of IRAP. Presently, binding of [(3)H]Ang IV and [(3)H]AL-11, a stable Ang IV analog, was compared on Chinese hamster ovary (CHO-K1) and mouse hippocampal (P40H1) cell membranes. With chelators, their high affinity sites showed the same pharmacological profile as for [(125)I]Ang IV binding. Without chelators, only high affinity binding was perceived for [(3)H]AL-11. The same pharmacological profile was recorded in both membrane preparations; it was different from the one in the presence of chelators and corresponded to catalytically active IRAP (despite the concurrent presence of aminopeptidase N (APN) in P40H1 cell membranes). This confirms that the active and apo-forms of IRAP have a distinct pharmacological profile.
Collapse
Affiliation(s)
- Heidi Demaegdt
- Research Group of Experimental Pharmacology, Department of Molecular and Biochemical Pharmacology, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Petrel C, Clauser E. Angiotensin II AT1 receptor constitutive activation: from molecular mechanisms to pathophysiology. Mol Cell Endocrinol 2009; 302:176-84. [PMID: 19061936 DOI: 10.1016/j.mce.2008.10.049] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2008] [Revised: 10/21/2008] [Accepted: 10/24/2008] [Indexed: 11/19/2022]
Abstract
Mutations activating the angiotensin II AT(1) receptor are important to identify and characterize because they give access to the activation mechanisms of this G protein coupled receptor and help to characterize the signaling pathways and the potential pathophysiology of this receptor. The different constitutively activated mutations of the AT(1) receptor are mostly localized in transmembrane domains (TM) and their characterization demonstrated that release of intramolecular constraints and movements among these TM are a necessary step for receptor activation. These mutations constitutively activate Gq linked signaling pathways, receptor internalization and maybe the G protein-independent signaling pathways. Expression of such mutations in mice is linked to hypertension and cardiovascular diseases, but such natural mutations have not been identified in human pathology.
Collapse
Affiliation(s)
- Christophe Petrel
- Institut Cochin, INSERM U567, University Paris Descartes, CNRS UMR8104, Paris, France
| | | |
Collapse
|
13
|
Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302:237-43. [PMID: 18620019 DOI: 10.1016/j.mce.2008.06.006] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2008] [Revised: 06/09/2008] [Accepted: 06/12/2008] [Indexed: 10/21/2022]
Abstract
Sartans are non-peptide AT(1) receptor antagonists used to treat hypertension and related pathologies. Their effects on the G protein-dependent responses of angiotensin II (Ang II) were the same in vascular tissues and in isolated cell systems. All are competitive but, when pre-incubated, they act surmountably (only rightward shift of the Ang II concentration-response curve) or insurmountably (also decreasing the maximal response). Insurmountable behaviour reflects the formation of tight sartan-receptor complexes; it is often partial due to the co-existence of tight and loose complexes. Their ratio positively correlates with the dissociation half-life of the tight complexes and depends on the sartan: i.e. candesartan>olmesartan>telmisartan approximately equal EXP3174>valsartan>irbesartan>>losartan. When AT(1) receptors display sufficient basal activity (in case of receptor over-expression, mutation and, especially, tissue stretching) sartans may also act as inverse agonists. This rather affects long-term, G protein-independent hypertrophic responses leading to cardiovascular remodelling.
Collapse
Affiliation(s)
- I Van Liefde
- Department of Molecular and Biochemical Pharmacology, Institute for Molecular Biology and Biotechnology, Vrije Universiteit Brussel (VUB), Brussel, Belgium
| | | |
Collapse
|
14
|
Akazawa H, Yasuda N, Komuro I. Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor. Mol Cell Endocrinol 2009; 302:140-7. [PMID: 19059460 DOI: 10.1016/j.mce.2008.11.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2008] [Revised: 11/06/2008] [Accepted: 11/06/2008] [Indexed: 11/23/2022]
Abstract
The angiotensin II (AngII) type 1 (AT(1)) receptor is a seven-transmembrane G protein-coupled receptor, and is involved in regulating the physiological and pathological process of the cardiovascular system. Systemically and locally generated AngII has agonistic action on AT(1) receptor, but recent studies have demonstrated that AT(1) receptor inherently shows spontaneous activity even in the absence of AngII. Furthermore, mechanical stress can activate AT(1) receptor by inducing conformational switch without the involvement of AngII, and induce cardiac hypertrophy in vivo. These agonist-independent activities of AT(1) receptor can be inhibited by inverse agonists, but not by neutral antagonists. Considerable attention has been directed to molecular mechanisms and clinical implications of agonist-independent AT(1) receptor activation, and inverse agonist activity emerges as an important pharmacological parameter for AT(1) receptor blockers that will improve efficacy and expand therapeutic potentials in cardiovascular medicine.
Collapse
Affiliation(s)
- Hiroshi Akazawa
- Division of Cardiovascular Pathophysiology, Chiba University Graduate School of Medicine, Chuo-ku, Chiba, Japan
| | | | | |
Collapse
|
15
|
Bhuiyan MA, Hossain M, Miura SI, Nakamura T, Ozaki M, Nagatomo T. Constitutively Active Mutant N111G of Angiotensin II Type 1 (AT1) Receptor Induces Homologous Internalization Through Mediation of AT1-Receptor Antagonist. J Pharmacol Sci 2009; 111:227-34. [DOI: 10.1254/jphs.09202fp] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
16
|
The human angiotensin AT(1) receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation. Eur J Pharmacol 2008; 590:255-63. [PMID: 18565507 DOI: 10.1016/j.ejphar.2008.05.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2007] [Revised: 04/07/2008] [Accepted: 05/13/2008] [Indexed: 01/14/2023]
Abstract
The angiotensin AT(1) receptor is a key regulator of blood pressure and body fluid homeostasis, and it plays a key role in the pathophysiology of several cardiovascular diseases such as hypertension, cardiac hypertrophy, congestive heart failure, and arrhythmia. The importance of human angiotensin AT(1) receptor signalling is illustrated by the common use of angiotensin AT(1) receptor-inverse agonists in clinical practice. It is well established that rodent orthologues of the angiotensin AT(1) receptor can selectively signal through G protein-dependent and -independent mechanisms in recombinant expression systems, primary cells and in vivo. The in vivo work clearly demonstrates profoundly different cellular consequences of angiotensin AT(1) receptor signalling in the cardiovascular system, suggesting pharmacological potential for drugs which specifically affect a subset of angiotensin AT(1) receptor actions. However, it is currently unknown whether the human angiotensin AT(1) receptor can signal through G protein-independent mechanisms - and if so, what the physiological impact of such signalling is. We have performed a detailed pharmacological analysis of the human angiotensin AT(1) receptor using a battery of angiotensin analogues and registered drugs targeting this receptor. We show that the human angiotensin AT(1) receptor signals directly through G protein-independent pathways and supports NIH3T3 cellular proliferation. The realization of G protein-independent signalling by the human angiotensin AT(1) receptor has clear pharmacological implications for development of drugs with pathway-specific actions and defined biological outcomes.
Collapse
|
17
|
Billet S, Bardin S, Verp S, Baudrie V, Michaud A, Conchon S, Muffat-Joly M, Escoubet B, Souil E, Hamard G, Bernstein KE, Gasc JM, Elghozi JL, Corvol P, Clauser E. Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest 2007; 117:1914-25. [PMID: 17607364 PMCID: PMC1890996 DOI: 10.1172/jci28764] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Accepted: 04/24/2007] [Indexed: 01/06/2023] Open
Abstract
The role of the renin-angiotensin system has been investigated by overexpression or inactivation of its different genes in animals. However, there is no data concerning the effect of the constitutive activation of any component of the system. A knockin mouse model has been constructed with a gain-of-function mutant of the Ang II receptor, type 1A (AT(1A)), associating a constitutively activating mutation (N111S) with a C-terminal deletion, which impairs receptor internalization and desensitization. In vivo consequences of this mutant receptor expression in homozygous mice recapitulate its in vitro characteristics: the pressor response is more sensitive to Ang II and longer lasting. These mice present with a moderate (~20 mmHg) and stable increase in BP. They also develop early and progressive renal fibrosis and cardiac fibrosis and diastolic dysfunction. However, there was no overt cardiac hypertrophy. The hormonal parameters (low-renin and inappropriately normal aldosterone productions) mimic those of low-renin human hypertension. This new model reveals that a constitutive activation of AT(1A) leads to cardiac and renal fibrosis in spite of a modest effect on BP and will be useful for investigating the role of Ang II in target organs in a model similar to some forms of human hypertension.
Collapse
Affiliation(s)
- Sandrine Billet
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sabine Bardin
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sonia Verp
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Véronique Baudrie
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Annie Michaud
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Sophie Conchon
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Martine Muffat-Joly
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Brigitte Escoubet
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Evelyne Souil
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Ghislaine Hamard
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Kenneth E. Bernstein
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jean Marie Gasc
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Jean-Luc Elghozi
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Pierre Corvol
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Eric Clauser
- Institut Cochin, Université Paris Descartes, CNRS UMR 8104, INSERM U567, Paris, France.
Faculté de Médecine Paris Descartes, INSERM U652, Université Paris Descartes, Paris, France.
INSERM U36, Collège de France, Paris, France.
INSERM IFR02, Centre d’Explorations Fonctionnelles Intégrées, Université Denis Diderot, Paris, France.
INSERM U772, Collège de France, Assistance Publique Hôpitaux de Paris, Hôpital Bichat–Claude Bernard, Paris, France.
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
| |
Collapse
|
18
|
Martin SS, Holleran BJ, Escher E, Guillemette G, Leduc R. Activation of the Angiotensin II Type 1 Receptor Leads to Movement of the Sixth Transmembrane Domain: Analysis by the Substituted Cysteine Accessibility Method. Mol Pharmacol 2007; 72:182-90. [PMID: 17446269 DOI: 10.1124/mol.106.033670] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The role of transmembrane domain six (TMD6) of the angiotensin II type 1 receptor, which is predicted to undergo conformational changes after agonist binding, was investigated using the substituted-cysteine accessibility method. Each residue in the Lys240-Leu265 fragment was mutated, one at a time, to a cysteine. The resulting mutants were expressed in COS-7 cells, which were subsequently treated with the charged sulfhydryl-specific alkylating agent methanethiosulfonate-ethylammonium (MTSEA). This treatment led to a significant reduction in binding of (125)I-[Sar(1),Ile(8)]AngII to the F249C, H256C, T260C, and V264C mutant receptors, suggesting that these residues orient themselves within the water-accessible binding pocket of the AT(1) receptor. It is noteworthy that this pattern of acquired MTSEA sensitivity was altered for TMD6 cysteines engineered in a constitutively active AT(1) receptor. Indeed, mutant F249C was insensitive to MTSEA treatment, whereas the sensitivity of mutant V264C decreased. Under these conditions, one other mutant, F261C, was found to be sensitive to MTSEA treatment. Our results suggest that constitutive activation of the AT(1) receptor causes TMD6 to pivot. This movement moves the top (extracellular side) of TMD6 toward the binding pocket and simultaneously distances the bottom (intracellular side) away from the binding pocket. Using this approach, we identified key elements within TMD6 that contribute to the activation of class A GPCRs through structural rearrangements.
Collapse
Affiliation(s)
- Stéphane S Martin
- Department of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001 12th Avenue North, Sherbrooke, Quebec, Canada, J1H 5N4
| | | | | | | | | |
Collapse
|
19
|
Souza‐Barbosa LA, Ferreira‐Melo SE, Ubaid‐Girioli S, Nogueira EA, Yugar‐Toledo JC, Moreno H. Endothelial Vascular Function in Hypertensive Patients After Renin—Angiotensin System Blockad. J Clin Hypertens (Greenwich) 2007; 8:803-811. [DOI: 10.1111/j.1524-6175.2006.05663.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Leon´ Adriana Souza‐Barbosa
- From the Laboratory of Cardiovascular Pharmacology and Hypertension, Departments of Pharmacology and Cardiology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - S´lvia E. Ferreira‐Melo
- From the Laboratory of Cardiovascular Pharmacology and Hypertension, Departments of Pharmacology and Cardiology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - Samira Ubaid‐Girioli
- From the Laboratory of Cardiovascular Pharmacology and Hypertension, Departments of Pharmacology and Cardiology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - Eduardo Arantes Nogueira
- From the Laboratory of Cardiovascular Pharmacology and Hypertension, Departments of Pharmacology and Cardiology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - Juan Carlos Yugar‐Toledo
- From the Laboratory of Cardiovascular Pharmacology and Hypertension, Departments of Pharmacology and Cardiology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - Heitor Moreno
- From the Laboratory of Cardiovascular Pharmacology and Hypertension, Departments of Pharmacology and Cardiology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| |
Collapse
|
20
|
Billet S, Bardin S, Tacine R, Clauser E, Conchon S. The AT1A receptor "gain-of-function" mutant N111S/delta329 is both constitutively active and hyperreactive to angiotensin II. Am J Physiol Endocrinol Metab 2006; 290:E840-8. [PMID: 16332920 DOI: 10.1152/ajpendo.00458.2005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The renin-angiotensin-aldosterone system (RAAS) is central to cardiovascular and renal physiology. However, there is no animal model in which the activation of the RAAS only reflects the activation of the angiotensin II (ANG II) AT1 receptor. As a first step to developing such a model, we characterized a gain-of-function mutant of the mouse AT1A receptor. This mutant carries two mutations: N111S predicted to activate the receptor constitutively and a COOH-terminal deletion, delta329, expected to reduce receptor internalization and desensitization. We expressed this double mutant (AT1A-N111S/delta329) in heterologous cells. It showed a pharmacological profile consistent with that of other constitutively active mutants. Furthermore, it increased basal production of inositol phosphates, as well as basal cytosolic and nuclear ERK activities. Basal proliferation of cells expressing the mutant was also greater than that of the wild type. The double mutant was poorly internalized and failed to recruit beta-arrestin 2 in the presence of ANG II. It also showed hypersensitive and hyperreactive responses to ANG II for both inositol phosphate production and ERK activation. The additivity of the phenotypes of the two mutations makes this mutant an appropriate candidate to test the physiological consequences of the AT1A receptor activation itself in transgenic animal models.
Collapse
Affiliation(s)
- Sandrine Billet
- Institut Cochin, Département d'Endocrinologie, Paris, France
| | | | | | | | | |
Collapse
|
21
|
Ellis J, Warburton P, Donnelly D, Balmforth AJ. Conformational induction is the key process for activation of the AT1 receptor. Biochem Pharmacol 2006; 71:464-71. [PMID: 16343447 DOI: 10.1016/j.bcp.2005.11.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2005] [Revised: 11/09/2005] [Accepted: 11/09/2005] [Indexed: 11/17/2022]
Abstract
It is currently unclear whether activation of the AT1 receptor by agonists involves conformational selection or induction. We evaluated the pharmacological properties of wild type and N111G CAM human AT1 receptors stably expressed in HEK293 cells. Although [Sar1]-Ang II and Ang IV were full agonists at both receptors, the potency of Ang IV was 280-fold lower at the wild type receptor. [Sar1, Ile8]-Ang II was only a full agonist at the N111G CAM AT1 receptor. [Sar1]-Ang II and [Sar1, Ile8]-Ang II displayed similar high affinity binding to both receptors. In contrast, Ang IV displayed low affinity binding to the wild type and high affinity binding to the N111G CAM AT1 receptor. Based on these observations we provide strong evidence that conformational induction is the key process for activation of the AT1 receptor. Only by the creation of CAMs can conformational selection be envisaged to take place.
Collapse
Affiliation(s)
- James Ellis
- Institute for Cardiovascular Research, University of Leeds, Leeds LS2 9JT, United Kingdom
| | | | | | | |
Collapse
|
22
|
Preto MAC, Melo A, Maia HLS, Mavromoustakos T, Ramos MJ. Molecular Dynamics Simulations of Angiotensin II in Aqueous and Dimethyl Sulfoxide Environments. J Phys Chem B 2005; 109:17743-51. [PMID: 16853269 DOI: 10.1021/jp0521048] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Angiotensin II (Ang II) is an octapeptidic hormone, which plays an important role in the mechanisms of blood pressure control. In this work, extensive molecular dynamics (MD) simulations have been carried out on this peptide, both in aqueous and in dimethyl sulfoxide (DMSO) environments. Experimentally proposed models for the structure of angiotensin II in both environments are not consensual and the results obtained have provided some further insight about the structural properties of this hormone. In these simulations, the N-terminus of Ang II in the aqueous environment has been associated with a considerable larger flexibility than the correspondent C-terminus, but this was not found in the case of the DMSO environment. This is consistent with the assumption that the biological activity of Ang II is associated with its C-terminal residues embedded in a hydrophobic environment of its AT1 receptor. Other features detected in DMSO environment were an H(His6 imidazole)-O(Phe8 carboxylate) hydrogen bond and a salt-bridge structure involving the Asp1 and Arg2 side chains. An additional important conformational feature is the spatial proximity between Tyr4 and His6 in both water and DMSO environments. This molecular feature may trigger the interest for the synthetic chemists to apply rational design for the synthesis of novel AT1 antagonists.
Collapse
Affiliation(s)
- Marco A C Preto
- REQUIMTE, Departamento de Química, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, 687, 4169-007 Porto, Portugal
| | | | | | | | | |
Collapse
|
23
|
Abstract
G protein-coupled receptors (GPCRs) were initially regarded to adopt an inactive and an active conformation and to activate a single type of G protein. Studies with recombinant cell systems have led to a more complex picture. First, GPCRs can activate distinct G protein species. Second, GPCR multistate models have been invoked to explain their complex behaviour in the presence of agonists, antagonists and other binding partners. The occurrence of intermediate receptor conformational states during GPCR activation and antagonist binding is suggested by fluorescence measurements and studies with constitutively active receptor mutants and insurmountable antagonists. Different agonists may trigger distinct effector pathways through a single receptor by dictating its preference for certain G proteins (i.e. 'agonist trafficking'). Structural modification and exogenous and endogenous (e.g. other cellular proteins, lipids) allosteric modulators also affect ligand-GPCR interaction and receptor activation. These new developments in GPCR research could lead to the development of more selective therapeutic drugs.
Collapse
Affiliation(s)
- G Vauquelin
- Department of Molecular and Biochemical Pharmacology, Institute for Molecular Biology and Biotechnology, Vrije Universiteit Brussel (VUB), Pleinlaan 2, B-1050 Brussel, Belgium. gvauquel@.vub.ac.be
| | | |
Collapse
|
24
|
Le MT, De Backer JP, Hunyady L, Vanderheyden PML, Vauquelin G. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol 2005; 513:35-45. [PMID: 15878707 DOI: 10.1016/j.ejphar.2005.02.029] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2004] [Revised: 02/08/2005] [Accepted: 02/10/2005] [Indexed: 11/16/2022]
Abstract
Chinese Hamster Ovary Cells (CHO-K1) were transiently and stably transfected to express the human angiotensin AT(1) receptor. Cell surface receptor expression was maximal 2 days after transient transfection. Their pharmacological and signalling properties differed from stably expressed receptors. Receptor reserve was significant in the transient cells but not in stable cells, explaining the higher potency of angiotensin II and the lower degree of insurmountable inhibition by candesartan in the transient cells. [Sar(1)Ile(8)]angiotensin II (sarile) is a potent angiotensin AT(1) receptor antagonist for the stable cells but is a partial agonist, producing 19% of the maximal response by angiotensin II, in transient cells. Internalization of [(3)H]angiotensin II and [(125)I]sarile (i.e., acid-resistant binding) was more pronounced in stable cells. CHO-K1 cells were also transiently transfected with the enhanced green fluorescence-AT(1) receptor gene. Confocal microscopy revealed rapid internalization induced by angiotensin II and sarile but not by candesartan. The above disparities may result from differences in receptor maturation and/or cellular surrounding.
Collapse
Affiliation(s)
- Minh Tam Le
- Department of Molecular and Biochemical Pharmacology, Institute for Molecular Biology and Biotechnology, Vrije Universiteit Brussel (VUB), Belgium.
| | | | | | | | | |
Collapse
|
25
|
Wamsley-Davis A, Padda R, Truong LD, Tsao CC, Zhang P, Sheikh-Hamad D. AT1A-mediated activation of kidney JNK1 and SMAD2 in obstructive uropathy: preservation of kidney tissue mass using candesartan. Am J Physiol Renal Physiol 2004; 287:F474-80. [PMID: 15126250 DOI: 10.1152/ajprenal.00452.2003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Literature suggests the involvement of the renin-angiotensin system and transforming growth factor (TGF)-β in the renal injury that follows chronic ureteric obstruction. SMAD proteins and the JNK1 cascade are essential components of TGF-β signaling machinery, and recent data suggest cooperative interaction between JNK1 and SMAD proteins in TGF-β-mediated gene expression. We used a rat model of chronic unilateral ureteric obstruction to study the effects of candesartan, an AT1A-receptor blocker, on tissue morphology and the activities of JNK1 and SMAD2 protein in the kidney. Ureteric obstruction for 28 days leads to interstitial fibrosis, tubule atrophy, and marked activation of SMAD2 and JNK1, without significant change in p38 kinase or ERK. Candesartan treatment, however, attenuated the chronic tubulointerstitial injury in obstructed kidneys and was associated with significant preservation of kidney tissue mass. Furthermore, treatment with candesartan diminished JNK1 activity and downregulated SMAD2 protein and activity in obstructed kidneys. In conclusion, obstructed kidneys showed chronic tubulointerstitial injury, which was associated with JNK1 and SMAD2 activation. The renoprotective effects afforded by AT1A-receptor blockade in obstructive uropathy are consistent with attenuation of JNK1- and SMAD2-mediated renal injury.
Collapse
Affiliation(s)
- Ann Wamsley-Davis
- Renal Section, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
| | | | | | | | | | | |
Collapse
|
26
|
Verheijen I, Tourlousse D, Vanderheyden PML, Backer JPD, Vauquelin G. Effect of saponin and filipin on antagonist binding to AT 1 receptors in intact cells. Biochem Pharmacol 2004; 67:1601-6. [PMID: 15041477 DOI: 10.1016/j.bcp.2004.01.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2003] [Accepted: 01/12/2004] [Indexed: 11/19/2022]
Abstract
In the present study, [ 3H ]-candesartan binding experiments were performed on intact Chinese Hamster Ovary cells transfected with the human AT1 receptor (CHO-AT1 cells). Cells were pre-treated with 0.01mg/ml saponin or filipin. Both pre-treatments resulted in an increased dissociation rate and decreased affinity of the insurmountable non-peptide antagonist [3H ]-candesartan. A similar decrease in affinity was observed for the peptide antagonist Sar1-Ile8 angiotensin II and for other non-peptide antagonists, irrespectively of their degree of insurmountability. A similar discrepancy in [ 3H ]-candesartan binding was earlier observed when comparing intact CHO-AT1 cells and membrane preparations thereof. This similarity is further highlighted by the observations that saponin or filipin no longer affect [ 3H ]-candesartan binding to CHO-AT1 cell membranes and that both agents permeabilise the CHO-AT1 cells. This suggests that the intracellular composition and/or organisation of living cells play an active role with regard to antagonist-AT1 receptor interactions.
Collapse
Affiliation(s)
- Ilse Verheijen
- Department of Molecular and Biochemical Pharmacology, Free University of Brussels (VUB), Pleinlaan 2, 1050 Brussels, Belgium.
| | | | | | | | | |
Collapse
|